Facebook
Twitter
LinkedIn
ForwardIn-person- Heart of the Matter: Improving Care and Outcomes in Patients with Cardiometabolic Disease
The prevalence of patients with chronic metabolic and cardiovascular multi-comorbidities has steadily increased over the last few decades. Optimal management of these complex cardiometabolic patients requires interdisciplinary collaboration between specialists to deliver prevention-focused treatment.
A remarkable shift in cardiometabolic disease prevention and treatment has recently occurred with the availability of glucose-lowering drugs with proven cardiorenal benefits in patients with and without type 2 diabetes mellitus (T2DM). Please join us to hear Dr. Mikhail Kosiborod discuss advancements on the front of cardiometabolic guideline-directed medical therapy (GDMT) and the applications for SGLT2 inhibitors and GLP1 receptor agonists as key components in this paradigm shift.
Target Audience
Cardiologists, primary care physicians, general internists, hospitalists, physician assistants, advanced practice registered nurses, nurses, pharmacists and other interested healthcare providers.
Learning Objectives
- Describe the effects of SGLT2 inhibitors on prevention and treatment of heart failure and kidney disease.
- Describe the effects of GLP1 receptor agonists on major adverse cardiovascular events in patients with type 2 diabetes.
- Utilize the current guideline recommendations for SGLT2 inhibitors and GLP1 receptor agonists from diabetes, cardiovascular and kidney professional societies.
Mikhail Kosiborod, M.D., FACC, FAHA
Executive Director, Cardiometabolic Center Alliance
Vice President for Research, Saint Luke's Health System
Professor of Medicine, University of Missouri-Kansas City School of Medicine
Kansas City, Missouri
Mikhail Kosiborod, M.D., faculty for this educational activity, is a consultant for 35Pharma, Alnylam, Amgen, Applied Therapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Imbria Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Merck (diabetes and cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, Regeneron, Roche, Sanofi, scPharmaceuticals, Structure Therapeutics, Vifor Pharma and Youngene Therapeutics. He receives research support from AstraZeneca and Vifor Pharma; is a speaker for AstraZeneca, Boehringer Ingelheim and Novo Nordisk; and has stock options for Artera Health and Saghmos Therapeutics. Dr. Kosiborod has indicated that the presentation or discussion will include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Jonathan Fialkow, M.D., director of this educational activity, has no relevant financial relationships with ineligible companies* to disclose.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-676407, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners, Nurses. Baptist Health South Florida CE Broker Provider #50-182.
AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC©) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC©). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.